Healy F, Turner A, Marensi V, MacEwan D
Front Pharmacol. 2024; 15:1441938.
PMID: 39372214
PMC: 11450236.
DOI: 10.3389/fphar.2024.1441938.
Furugaki K, Fujimura T, Sakaguchi N, Watanabe Y, Uchibori K, Miyauchi E
Mol Oncol. 2024; 19(2):519-539.
PMID: 39369284
PMC: 11793004.
DOI: 10.1002/1878-0261.13746.
Khan S, Cao L, Wiegand J, Zhang P, Zajac-Kaye M, Kaye F
bioRxiv. 2024; .
PMID: 38464204
PMC: 10925307.
DOI: 10.1101/2024.02.27.582353.
Pal Choudhuri S, Girard L, Lim J, Wise J, Freitas B, Yang D
Cancer Discov. 2024; 14(5):804-827.
PMID: 38386926
PMC: 11061613.
DOI: 10.1158/2159-8290.CD-23-0656.
Leon C, Manley Jr E, Neely A, Castillo J, Ramos Correa M, Velarde D
Front Oncol. 2023; 13():1187585.
PMID: 38023251
PMC: 10651223.
DOI: 10.3389/fonc.2023.1187585.
A dual role for ERK-1/2 in the regulation of plasmin activity and cell migration in metastatic NSCLC-H1299 cells.
Zeitlmayr S, Cami D, Selmani B, Gudermann T, Breit A
Arch Toxicol. 2023; 97(12):3113-3128.
PMID: 37712947
PMC: 10567951.
DOI: 10.1007/s00204-023-03600-6.
Design and Characterization of a Multistage Peptide-Based Vaccine Platform to Target Infection.
Bellini C, Vergara E, Bencs F, Fodor K, Bosze S, Krivic D
Bioconjug Chem. 2023; 34(10):1738-1753.
PMID: 37606258
PMC: 10587871.
DOI: 10.1021/acs.bioconjchem.3c00273.
Silencing of induces epithelial‑to‑mesenchymal transition in lung cancer cell lines with different effects on proliferation and clonogenic growth.
Kawabe N, Matsuoka K, Komeda K, Muraki N, Takaba M, Togami Y
Oncol Lett. 2023; 26(3):391.
PMID: 37600329
PMC: 10433723.
DOI: 10.3892/ol.2023.13977.
Friend or Foe: Regulation, Downstream Effectors of RRAD in Cancer.
Sun Z, Li Y, Tan X, Liu W, He X, Pan D
Biomolecules. 2023; 13(3).
PMID: 36979412
PMC: 10046484.
DOI: 10.3390/biom13030477.
Preclinical Models of Neuroendocrine Neoplasia.
Sedlack A, Saleh-Anaraki K, Kumar S, Ear P, Lines K, Roper N
Cancers (Basel). 2022; 14(22).
PMID: 36428741
PMC: 9688518.
DOI: 10.3390/cancers14225646.
SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression.
Niemeyer D, Stenzel S, Veith T, Schroeder S, Friedmann K, Weege F
PLoS Biol. 2022; 20(11):e3001871.
PMID: 36383605
PMC: 9710838.
DOI: 10.1371/journal.pbio.3001871.
Water-Soluble Truncated Fatty Acid-Porphyrin Conjugates Provide Photo-Sensitizer Activity for Photodynamic Therapy in Malignant Mesothelioma.
Bonsall S, Hubbard S, Jithin U, Anslow J, Todd D, Rowding C
Cancers (Basel). 2022; 14(21).
PMID: 36358864
PMC: 9654571.
DOI: 10.3390/cancers14215446.
Tri-Channel Electrochemical Immunobiosensor for Combined Detections of Multiple Exosome Biomarkers of Lung Cancer.
Fan C, Jiang B, Shi W, Chen D, Zhou M
Biosensors (Basel). 2022; 12(7).
PMID: 35884238
PMC: 9313016.
DOI: 10.3390/bios12070435.
Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.
Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch A
Nat Commun. 2022; 13(1):4327.
PMID: 35882862
PMC: 9325712.
DOI: 10.1038/s41467-022-31963-4.
The Inhibitory Effects of Anti-ERC/Mesothelin Antibody 22A31 on Colorectal Adenocarcinoma Cells, within a Mouse Xenograft Model.
Taniguchi G, Kajino K, Momose S, Saeki H, Yue L, Ohtsuji N
Cancers (Basel). 2022; 14(9).
PMID: 35565327
PMC: 9101225.
DOI: 10.3390/cancers14092198.
Resistance to mutant KRAS-induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell line.
Muraki N, Yamada M, Doki H, Nakai R, Komeda K, Goto D
Exp Cell Res. 2022; 414(1):113053.
PMID: 35149086
PMC: 10228173.
DOI: 10.1016/j.yexcr.2022.113053.
Inhibition of Non-Small Cell Lung Cancer Proliferation and Survival by Rosemary Extract Is Associated with Activation of ERK and AMPK.
ONeill E, Moore J, Song J, Tsiani E
Life (Basel). 2022; 12(1).
PMID: 35054445
PMC: 8779065.
DOI: 10.3390/life12010052.
Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity.
Tully K, Tendler S, Carter L, Sharma S, Samuels Z, Mandleywala K
Clin Cancer Res. 2022; 28(7):1391-1401.
PMID: 35046060
PMC: 8976830.
DOI: 10.1158/1078-0432.CCR-21-1533.
TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin.
Hinz T, Kalkur R, Rabinovitch J, Hinkle W, Heasley L
Mol Pharmacol. 2021; 100(2):144-154.
PMID: 34031188
PMC: 11037449.
DOI: 10.1124/molpharm.121.000254.
Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.
Aydemirli M, van Eendenburg J, van Wezel T, Oosting J, Corver W, Kapiteijn E
Endocr Relat Cancer. 2021; 28(6):377-389.
PMID: 33878728
PMC: 8183637.
DOI: 10.1530/ERC-20-0436.